IDH1 and glioblastoma: For instance, IDH1 knockdown in GBM cells increases the efficacy of the alkylating agent/glutathione reductase inhibitor bis-chloroethylnitrosourea (BCNU), which is clinically used as biodegradable wafers after surgical resection, and to the further addition of aminooxyacetate, a transaminase and glutaminolysis inhibitor.